Androgenetic alopecia. Male-pattern baldness
Conditions
Interventions
Intervention 1: Intervention group: Oral consumption of saw palmetto extract 320 mg daily for 6 months. Intervention 2: Control group: Consumption of oral finasteride 1 mg daily for 6 months.
Treatment - Drugs
Intervention group: Oral consumption of saw palmetto extract 320 mg daily for 6 months
Control group: Consumption of oral finasteride 1 mg daily for 6 months
Sponsors
Vice chancellor for reasearch of Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 41 Years
Inclusion criteria
Inclusion criteria: Healthy male subjects between 18 to 41 years old with grade 1 or higher androgenetic alopecia (according to Hamilton-Norwood criteria) without any systemic diseases or organ dysfunction who seek for treatment of their balding scalp that have no history of taking medications effective on hair-growth or hair-loss during the past year and who consent to be included in the trial. Exclusion criteria include: occurence of potentially life-threatening side-effects or any adverse effect that is not tolerable by the patient, discontinuation of the edication or intentional use of other medications concurrently which are effective on hair growth.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of hair follicles in one centimeter squar of the sagital scalp. Timepoint: Before the intervention and 6 months after the intervention. Method of measurement: Cutting the hair in one centimeter area of an specified area of the scalp and photography from this region for counting the hair follicles. | — |
Secondary
| Measure | Time frame |
|---|---|
| Aspartate transaminase. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Alanine transaminase. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Alkaline phosphatase. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Bilirubin (total). Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Bilirubin (direct). Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Amylase. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Lipase. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Triglyceride. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Total cholesterol. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Low density lipoprotein. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;High density lipoprotein. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Partial thromboplastine time. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;International normalized ratio. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Bleeding time. Timepoint: before and 6 month after the intervention. Method of measurement: by coagulation technologist.;Total testosterone. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Free testosterone. Timepoint: before and 6 month after the intervention. Method of measurement: measurement in serum.;Dihydrotestosterone. Timepoint: before and 6 month after the intervention. Method of | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Pardis Hejazi
Razi Dermatology Hospital
Outcome results
None listed